Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00116415
Status:
COMPLETED
Last Update Posted:
2011-04-22
First Post:
2005-06-29
Brief Title:
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Daily Antiretroviral Therapy DART 1 An Open-Label Single-Arm Prospective Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated Ddl-EC in Combination With Lamivudine 3TC and Efavirenz EFV Once Daily in Anti-Retroviral Therapy ART Naive HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz EFV didanosine ddI-EC and lamivudine 3TC leads to improved outcomes as measured by viral load CD4 counts adherence safety and tolerability
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None